PeptidePros

Compare · Head-to-head

Follistatin vs Hexarelin.

Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.

Which should you research first?

Start with Hexarelin, then use the table to confirm fit.

Hexarelin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.

Comparison next step

Personalize this head-to-head.

Take the quiz before converting a comparison into a compound, vendor, or protocol decision.

01· Subject

Follistatin

Myostatin/activin antagonist — human work is largely via gene therapy, not consumer peptide vials.

Tier C-Dextreme risk

02· Subject

Hexarelin

GHRP-class secretagogue with stronger GH stimulation and studied sleep-endocrine effects.

Tier B-Chigh risk

01 · At a glance

Decision factorFollistatinHexarelin
Primary fitmuscle growth & strength research where you want a clear starting pointmuscle growth & strength and sleep & relaxation comparisons
EvidenceTier C-DTier B-C
Riskextremehigh
Experience leveladvancedadvanced
Budget tierpremiummid
Administration routesubcutaneoussubcutaneous, intravenous

02 · Use case & timing

Decision factorFollistatinHexarelin
Goal fitMuscle Growth & StrengthMuscle Growth & Strength, Sleep & Relaxation, GH Axis Optimization
What users compare it forMyostatin inhibition / muscle growth narrative. Legitimate modality is gene therapy, not RUO peptide.GH-axis modulation; sleep architecture research interest.
Onset timelineGene therapy effects measured over months. Consumer peptide timelines are speculative.Acute endocrine effects; sleep effects studied overnight.
Main tradeoffPotential upside comes with much more safety and screening caution than lower-risk alternatives.Potential upside comes with much more safety and screening caution than lower-risk alternatives.

03 · Safety & restrictions

Decision factorFollistatinHexarelin
Adverse effectsSystemic muscle-growth modulation carries theoretical off-target risks; extreme risk.Endocrine spillover (ACTH, cortisol, prolactin).
ContraindicationsNo consumer-grade data.No formal label.
Interaction notesUnknown; likely interacts with anabolic pathways and endocrine status.Unknown; caution with other GH-axis compounds.
Regulatory statusNot approvedNot approved
FDA flagFDA status unclearFDA status unclear
WADA statusStatus unclearWADA S2

04 · Age & monitoring

Decision factorFollistatinHexarelin
Supported age rangesNo age guidance yetNo age guidance yet
Life-stage noteNot yet documentedNot yet documented
Monitoring burdenNot specifiedNot specified
Follow-up cadenceNot yet documentedNot yet documented

05 · Cost & sourcing

Decision factorFollistatinHexarelin
Typical cycle costNo reliable estimate yetNo reliable estimate yet
Estimated monthly costNo reliable estimate yetNo reliable estimate yet
Cost confidenceNo estimateNo estimate

06 · Before you buy

Decision factorFollistatinHexarelin
Tracked vendor listings0 listings0 listings
Sourcing noteNo tracked product page yet, so sourcing takes more manual review.No tracked product page yet, so sourcing takes more manual review.
Stack-friendly?Usually stack-friendlyUsually stack-friendly

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Still deciding

Get a plan tailored to you.

The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.